董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Heinz Mausli | 男 | Director | 57 | 未披露 | 未持股 | 2020-03-13 |
| Gerard Ber | 男 | Director | 62 | 未披露 | 未持股 | 2020-03-13 |
| David W. Mims | 男 | Interim CEO and Director | 57 | 未披露 | 未持股 | 2020-03-13 |
| Eric J. Ende | 男 | Director | 51 | 未披露 | 未持股 | 2020-03-13 |
| Ann MacDougall | 女 | Interim Chair | 66 | 未披露 | 未持股 | 2020-03-13 |
| Eric J. Ende | 男 | Director | 51 | 未披露 | 未持股 | 2020-03-13 |
| Bradley L. Campbell | 男 | Director | 44 | 未披露 | 未持股 | 2020-03-13 |
| Karen J. Ferrante | 女 | Director | 62 | 16.81万美元 | 未持股 | 2020-03-13 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Patrick Fabbio | 男 | Executive Vice President and Chief Financial Officer | 52 | 68.82万美元 | 未持股 | 2020-03-13 |
| Asha Das | 女 | Chief Medical Officer | 55 | 未披露 | 未持股 | 2020-03-13 |
| David W. Mims | 男 | Interim CEO and Director | 57 | 未披露 | 未持股 | 2020-03-13 |
| Bryce Tenbarge | 男 | Senior Vice President, Commercial | 47 | 未披露 | 未持股 | 2020-03-13 |
| Benedict Osorio | 男 | Chief Operating Officer | 63 | 79.38万美元 | 未持股 | 2020-03-13 |
| Vivien Wong | 女 | Executive Vice President, Development | 63 | 84.09万美元 | 未持股 | 2020-03-13 |
董事简历
中英对照 | 中文 | 英文- Heinz Mausli
-
Heinz Mausli，现任首席财务官；2008-2014，担任本公司董事。他于2003年加入AAA。他还是AAA一些子公司的董事。加入AAA之前，1996-2001，他是Accenture的管理顾问；1995-1996，担任Gemini Consulting的管理顾问。1988年，他在瑞士St. Gallen的University of St. Gallen获得硕士学位；1994年，在纽约州纽约市Columbia Business School获得工商管理硕士学位。
Heinz Mausli is a Director and a member of the Audit Committee and Compensation Committee, serving on the Board of Directors since June 2020. He is also a member of the Board of Directors of Inventiva SA. He served on the Board of Directors and as the Chairperson of the Audit Committee of Progenics until its acquisition by the Company. Mr. Musli is the former Chief Financial Officer of Advanced Accelerator Applications S.A., previously serving on its board and also on the executive team that managed its integration into Novartis AG after helping it grow into a global leader within its field. Mr. Musli previously worked as a management consultant for a number of strategy projects in both Europe and the United States for Accenture and Gemini Consulting, as well as independently. - Heinz Mausli，现任首席财务官；2008-2014，担任本公司董事。他于2003年加入AAA。他还是AAA一些子公司的董事。加入AAA之前，1996-2001，他是Accenture的管理顾问；1995-1996，担任Gemini Consulting的管理顾问。1988年，他在瑞士St. Gallen的University of St. Gallen获得硕士学位；1994年，在纽约州纽约市Columbia Business School获得工商管理硕士学位。
- Heinz Mausli is a Director and a member of the Audit Committee and Compensation Committee, serving on the Board of Directors since June 2020. He is also a member of the Board of Directors of Inventiva SA. He served on the Board of Directors and as the Chairperson of the Audit Committee of Progenics until its acquisition by the Company. Mr. Musli is the former Chief Financial Officer of Advanced Accelerator Applications S.A., previously serving on its board and also on the executive team that managed its integration into Novartis AG after helping it grow into a global leader within its field. Mr. Musli previously worked as a management consultant for a number of strategy projects in both Europe and the United States for Accenture and Gemini Consulting, as well as independently.
- Gerard Ber
-
Gerard Ber，现任首席运营官；2002-2004，担任本公司董事。他于2002年加入AAA。此前，2000-2002，他是 OM Pharma的西欧地区总监；1994-2000，担任CIS Medipro的总监、营销与商务总监；1984-1994，在CIS Bio International担任过各种管理职务。他还是AAA一些子公司的董事。1983年，1984年，他在法国Grenoble的Université Scientifique et Médicale de Grenoble分别获得药剂学博士学位、食品高级研究硕士学位；1984年，在法国巴黎的Institut de Pharmacie Industrielle de Paris获得营销与国际商务学位。
Gerard Ber is a Director and a member of the Science and Technology Committee, serving on the Board since June 2020. Dr. Ber is also a member of the Board of Y-mAbs Therapeutics, Inc. He served on the Board of Directors of Progenics until its acquisition by the Company. Dr. Ber was also the Co-Founder and former Chief Operating Officer of Advanced Accelerator Applications S.A. until its acquisition by Novartis AG. - Gerard Ber，现任首席运营官；2002-2004，担任本公司董事。他于2002年加入AAA。此前，2000-2002，他是 OM Pharma的西欧地区总监；1994-2000，担任CIS Medipro的总监、营销与商务总监；1984-1994，在CIS Bio International担任过各种管理职务。他还是AAA一些子公司的董事。1983年，1984年，他在法国Grenoble的Université Scientifique et Médicale de Grenoble分别获得药剂学博士学位、食品高级研究硕士学位；1984年，在法国巴黎的Institut de Pharmacie Industrielle de Paris获得营销与国际商务学位。
- Gerard Ber is a Director and a member of the Science and Technology Committee, serving on the Board since June 2020. Dr. Ber is also a member of the Board of Y-mAbs Therapeutics, Inc. He served on the Board of Directors of Progenics until its acquisition by the Company. Dr. Ber was also the Co-Founder and former Chief Operating Officer of Advanced Accelerator Applications S.A. until its acquisition by Novartis AG.
- David W. Mims
-
DavidW.Mims，临时首席执行官，于2019年11月加入董事会。Mims先生自2017年5月起担任Guideway Care（一家梦百合公司，提供技术支持的护理指导）和SouthPoint Bank（一家社区银行机构）的董事会成员。此前，2011年5月至2014年5月，Mims先生曾担任私人制药公司Aptalis Pharma Inc.（F/K/A Axcan Pharma Inc.）的美国专业制药总裁，该公司被森林实验室公司（纽约证券交易所代码:FRX）收购后不久，他在该公司管理着200多名员工。Mims从2008年2月到2014年5月担任Axcan Intermediate Holdings Inc.（Axcan Pharma Inc.（前身为TSE:AXP和NASDAQ:AXCA）母公司）美国专业制药总裁，从2000年到2007年担任董事会成员。Mims先生于2000年开始在Axcan Pharma Inc.担任执行Vice President和首席运营官，此前该公司收购了ScandiPharm，Inc.，后者是一家私人控股的制药公司，Mims先生帮助建立了该公司，他曾担任该公司的Vice President、首席运营官和首席财务官，从1991年到1998年。目前，Mims先生担任美国注册会计师协会和阿拉巴马注册会计师协会的成员。此前，Mims先生担任阿拉巴马大学伯明翰研究基金会（University of Alabama at Birmingham Research Foundation）的董事。Mims先生是一名有执照的注册会计师（不活跃）。Mims先生在奥本大学（Auburn University）获得会计学学士学位。
David W. Mims, Interim CEO, joined our Board in November 2019. Mr. Mims has served as a member of the board of directors at each of Guideway Care, a healthcare company that provides technology-enabled care guidance, since May 2017 and SouthPoint Bank, a community banking institution, since August 2015. Previously, Mr. Mims served as President at U.S. Specialty Pharmaceuticals for Aptalis Pharma Inc. “Aptalis” (f/k/a Axcan Pharma Inc.), a privately held pharmaceutical company, from May 2011 until May 2014 shortly after it was acquired by Forest Laboratories, Inc. (formerly NYSE: FRX) and where he managed over 200 employees. Mr. Mims similarly served as President of U.S. Specialty Pharmaceuticals at Axcan Intermediate Holdings Inc., the parent company of Axcan Pharma Inc. (formerly TSE: AXP and NAsdaq: AXCA), from February 2008 until May 2014 and as a member on its board from 2000 to 2007. Mr. Mims began working at Axcan Pharma Inc. as Executive Vice President and Chief Operating Officer in 2000 after the company acquired Scandipharm, Inc., a privately held pharmaceutical company, which Mr. Mims helped found and for which he served as Vice President, Chief Operating Officer and Chief Financial Officer, from 1991 until 1998. Currently, Mr. Mims serves as a member of the American Institute of Certified Public Accountants and Alabama Society of Certified Public Accountants. Previously, Mr. Mims served as a director of the University of Alabama at Birmingham Research Foundation. Mr. Mims is a licensed CPA (inactive). Mr. Mims received his B.S. in accounting from Auburn University. - DavidW.Mims，临时首席执行官，于2019年11月加入董事会。Mims先生自2017年5月起担任Guideway Care（一家梦百合公司，提供技术支持的护理指导）和SouthPoint Bank（一家社区银行机构）的董事会成员。此前，2011年5月至2014年5月，Mims先生曾担任私人制药公司Aptalis Pharma Inc.（F/K/A Axcan Pharma Inc.）的美国专业制药总裁，该公司被森林实验室公司（纽约证券交易所代码:FRX）收购后不久，他在该公司管理着200多名员工。Mims从2008年2月到2014年5月担任Axcan Intermediate Holdings Inc.（Axcan Pharma Inc.（前身为TSE:AXP和NASDAQ:AXCA）母公司）美国专业制药总裁，从2000年到2007年担任董事会成员。Mims先生于2000年开始在Axcan Pharma Inc.担任执行Vice President和首席运营官，此前该公司收购了ScandiPharm，Inc.，后者是一家私人控股的制药公司，Mims先生帮助建立了该公司，他曾担任该公司的Vice President、首席运营官和首席财务官，从1991年到1998年。目前，Mims先生担任美国注册会计师协会和阿拉巴马注册会计师协会的成员。此前，Mims先生担任阿拉巴马大学伯明翰研究基金会（University of Alabama at Birmingham Research Foundation）的董事。Mims先生是一名有执照的注册会计师（不活跃）。Mims先生在奥本大学（Auburn University）获得会计学学士学位。
- David W. Mims, Interim CEO, joined our Board in November 2019. Mr. Mims has served as a member of the board of directors at each of Guideway Care, a healthcare company that provides technology-enabled care guidance, since May 2017 and SouthPoint Bank, a community banking institution, since August 2015. Previously, Mr. Mims served as President at U.S. Specialty Pharmaceuticals for Aptalis Pharma Inc. “Aptalis” (f/k/a Axcan Pharma Inc.), a privately held pharmaceutical company, from May 2011 until May 2014 shortly after it was acquired by Forest Laboratories, Inc. (formerly NYSE: FRX) and where he managed over 200 employees. Mr. Mims similarly served as President of U.S. Specialty Pharmaceuticals at Axcan Intermediate Holdings Inc., the parent company of Axcan Pharma Inc. (formerly TSE: AXP and NAsdaq: AXCA), from February 2008 until May 2014 and as a member on its board from 2000 to 2007. Mr. Mims began working at Axcan Pharma Inc. as Executive Vice President and Chief Operating Officer in 2000 after the company acquired Scandipharm, Inc., a privately held pharmaceutical company, which Mr. Mims helped found and for which he served as Vice President, Chief Operating Officer and Chief Financial Officer, from 1991 until 1998. Currently, Mr. Mims serves as a member of the American Institute of Certified Public Accountants and Alabama Society of Certified Public Accountants. Previously, Mr. Mims served as a director of the University of Alabama at Birmingham Research Foundation. Mr. Mims is a licensed CPA (inactive). Mr. Mims received his B.S. in accounting from Auburn University.
- Eric J. Ende
-
EricJ.Ende于2019年11月加入我们的董事会。Ende自2009年起担任Ende Biomedical Consulting Group“；Ende Biomed”；总裁。Ende Biomed专注于帮助生命科学公司筹集资本，确定许可合作伙伴和收购方，并优化公司结构。此外，它还分析了生命科学行业客户的私人和公共投资机会。Ende博士还帮助激进投资者在公司董事会获得席位。Ende从2010年到2011年担任Genzyme Corporation董事，直到2011年被Sanofi-Aventis收购。在Genzyme&8217；s董事会任职期间，他是审计和风险管理委员会的成员。Ende博士目前是Matinas Biopharma的董事会成员，在那里他是薪酬委员会主席，并在审计以及提名与治理委员会任职。Ende博士也是Avadel plc的董事会成员，在那里他是提名&公司治理委员会的主席，并在审计和薪酬委员会任职。Ende博士也是Mount Sinai Innovation Partners的技术转让委员会成员。他还担任无担保债权人委员会主席，监督Egenix Inc.的破产和随后的清算信托委员会主席，从2002年到2008年，Ende博士是Merrill Lynch的高级生物技术分析师。从2000年到2002年，Ende博士是Banc of America Securities的高级生物技术分析师。从1997年到2000年，他曾担任Lehman Brothers公司的生物技术分析师。在恩德博士担任生物技术分析师的职业生涯中，他曾六次被任命为机构投资者全美股票研究团队以及Greenwich调查的顶级分析师名单。他还被Street.com评为最佳股票选择者，并被Forbes.com.Dr.评为最佳收益估算者。Ende于1997年获得NYU-Stern Business School金融和会计工商管理硕士学位，于1994年获得Mount Sinai School of Medicine医学博士学位，并于1990年获得Emory University生物学和心理学学士学位。
Eric J. Ende, has been a member of the Board since December 2018. Dr. Ende is the President of Ende BioMedical Consulting Group, a privately held consulting company focused on the life sciences industry, a position he has held since 2009. Since May 2017 Dr. Ende has been a member of the board of directors of Matinas BioPharma, Inc., a clinical-stage biopharmaceutical company, where he chairs the Compensation Committee and serves on the Audit Committee. From November 2019 to June 2020 Dr. Ende served on the board of directors of Progenics Pharmaceuticals, Inc., a biopharmaceutical company. From January 2015 to October 2016 he served as Chairman of the Unsecured Creditor's Committee in the bankruptcy of Egenix, Inc. From 2010 to 2011 Dr. Ende served on the board of directors and as a member of the Audit and Risk Management Committees of Genzyme Corp., a biotechnology company, until it was acquired in 2011 by Sanofi S.A. From 2002 through 2008 Dr. Ende was the senior biotechnology analyst at Merrill Lynch; from 2000 through 2002 he was the senior biotechnology analyst at Bank of America Securities; and from 1997 to 2000 he was a biotechnology analyst at Lehman Brothers. Dr. Ende received an MBA in Finance and Accounting from NYU - Stern Business School in 1997 an MD from Mount Sinai School of Medicine in 1994 and a BS in Biology and Psychology from Emory University in 1990. - EricJ.Ende于2019年11月加入我们的董事会。Ende自2009年起担任Ende Biomedical Consulting Group“；Ende Biomed”；总裁。Ende Biomed专注于帮助生命科学公司筹集资本，确定许可合作伙伴和收购方，并优化公司结构。此外，它还分析了生命科学行业客户的私人和公共投资机会。Ende博士还帮助激进投资者在公司董事会获得席位。Ende从2010年到2011年担任Genzyme Corporation董事，直到2011年被Sanofi-Aventis收购。在Genzyme&8217；s董事会任职期间，他是审计和风险管理委员会的成员。Ende博士目前是Matinas Biopharma的董事会成员，在那里他是薪酬委员会主席，并在审计以及提名与治理委员会任职。Ende博士也是Avadel plc的董事会成员，在那里他是提名&公司治理委员会的主席，并在审计和薪酬委员会任职。Ende博士也是Mount Sinai Innovation Partners的技术转让委员会成员。他还担任无担保债权人委员会主席，监督Egenix Inc.的破产和随后的清算信托委员会主席，从2002年到2008年，Ende博士是Merrill Lynch的高级生物技术分析师。从2000年到2002年，Ende博士是Banc of America Securities的高级生物技术分析师。从1997年到2000年，他曾担任Lehman Brothers公司的生物技术分析师。在恩德博士担任生物技术分析师的职业生涯中，他曾六次被任命为机构投资者全美股票研究团队以及Greenwich调查的顶级分析师名单。他还被Street.com评为最佳股票选择者，并被Forbes.com.Dr.评为最佳收益估算者。Ende于1997年获得NYU-Stern Business School金融和会计工商管理硕士学位，于1994年获得Mount Sinai School of Medicine医学博士学位，并于1990年获得Emory University生物学和心理学学士学位。
- Eric J. Ende, has been a member of the Board since December 2018. Dr. Ende is the President of Ende BioMedical Consulting Group, a privately held consulting company focused on the life sciences industry, a position he has held since 2009. Since May 2017 Dr. Ende has been a member of the board of directors of Matinas BioPharma, Inc., a clinical-stage biopharmaceutical company, where he chairs the Compensation Committee and serves on the Audit Committee. From November 2019 to June 2020 Dr. Ende served on the board of directors of Progenics Pharmaceuticals, Inc., a biopharmaceutical company. From January 2015 to October 2016 he served as Chairman of the Unsecured Creditor's Committee in the bankruptcy of Egenix, Inc. From 2010 to 2011 Dr. Ende served on the board of directors and as a member of the Audit and Risk Management Committees of Genzyme Corp., a biotechnology company, until it was acquired in 2011 by Sanofi S.A. From 2002 through 2008 Dr. Ende was the senior biotechnology analyst at Merrill Lynch; from 2000 through 2002 he was the senior biotechnology analyst at Bank of America Securities; and from 1997 to 2000 he was a biotechnology analyst at Lehman Brothers. Dr. Ende received an MBA in Finance and Accounting from NYU - Stern Business School in 1997 an MD from Mount Sinai School of Medicine in 1994 and a BS in Biology and Psychology from Emory University in 1990.
- Ann MacDougall
-
Ann MacDougall于2019年11月加入我们的董事会。MacDougall女士是一位经验丰富的执行官，律师和影响投资者。她共同创立了Dunollie基金，自2018年1月起担任首席执行官。MacDougall女士自2017年11月起还担任Encore.org的高级顾问，Encore.org是一家全国性组织，致力于为在公共或非营利服务领域发展第二职业的个人开展运动，她还于2014年1月至2017年10月担任总裁。从2007年到2012年，她曾担任Acumen公司（全球投资基金，专注于低收入客户的商品和服务）的首席运营官。从1990年到2007年，她曾任职普华永道会计师事务所（PricewaterhouseCoopers LLP），从事法律和管理职业，包括担任美国公司的总法律顾问/管理委员会成员，以及位于巴黎的全球副总法律顾问。MacDougall女士是OpiantPharmaceuticals，Inc.的董事会成员，她在该公司担任薪酬委员会主席，并是治理和提名委员会的成员，也是ATMOS XR（一家技术公司）的董事会成员。她在Tufts University获得文学学士学位，在Brooklyn Law School获得法学博士学位，还是Harvard Advanced Leadership Initiative的研究员。
Ann MacDougall joined our Board in November 2019. Ms. MacDougall is an experienced executive, attorney and impact investor. She co-founded the Dunollie Fund, where she has served as chief executive officer since January 2018. Ms. MacDougall has also served since November 2017 as a Senior Advisor at Encore.org, a national organization building a movement for individuals developing second careers in public or non-profit service, where she also served as President from January 2014 through October 2017. From 2007 to 2012 she was chief operating officer of Acumen, a global investment fund focused on goods and services for low-income customers. From 1990 to 2007 she had a legal and management career at PriceWaterhouseCoopers LLP, including as General Counsel/Management Committee Member of the U.S. firm and Global Deputy General Counsel based in Paris. Ms. MacDougall sits on the board of Opiant Pharmaceuticals, Inc. where she chairs the Compensation Committee and is a member of the Governance and Nominations Committee, and also on the board of Atmos XR, a technology company. She earned her BA at Tufts University, her J.D. at Brooklyn Law School and was a fellow at the Harvard Advanced Leadership Initiative. - Ann MacDougall于2019年11月加入我们的董事会。MacDougall女士是一位经验丰富的执行官，律师和影响投资者。她共同创立了Dunollie基金，自2018年1月起担任首席执行官。MacDougall女士自2017年11月起还担任Encore.org的高级顾问，Encore.org是一家全国性组织，致力于为在公共或非营利服务领域发展第二职业的个人开展运动，她还于2014年1月至2017年10月担任总裁。从2007年到2012年，她曾担任Acumen公司（全球投资基金，专注于低收入客户的商品和服务）的首席运营官。从1990年到2007年，她曾任职普华永道会计师事务所（PricewaterhouseCoopers LLP），从事法律和管理职业，包括担任美国公司的总法律顾问/管理委员会成员，以及位于巴黎的全球副总法律顾问。MacDougall女士是OpiantPharmaceuticals，Inc.的董事会成员，她在该公司担任薪酬委员会主席，并是治理和提名委员会的成员，也是ATMOS XR（一家技术公司）的董事会成员。她在Tufts University获得文学学士学位，在Brooklyn Law School获得法学博士学位，还是Harvard Advanced Leadership Initiative的研究员。
- Ann MacDougall joined our Board in November 2019. Ms. MacDougall is an experienced executive, attorney and impact investor. She co-founded the Dunollie Fund, where she has served as chief executive officer since January 2018. Ms. MacDougall has also served since November 2017 as a Senior Advisor at Encore.org, a national organization building a movement for individuals developing second careers in public or non-profit service, where she also served as President from January 2014 through October 2017. From 2007 to 2012 she was chief operating officer of Acumen, a global investment fund focused on goods and services for low-income customers. From 1990 to 2007 she had a legal and management career at PriceWaterhouseCoopers LLP, including as General Counsel/Management Committee Member of the U.S. firm and Global Deputy General Counsel based in Paris. Ms. MacDougall sits on the board of Opiant Pharmaceuticals, Inc. where she chairs the Compensation Committee and is a member of the Governance and Nominations Committee, and also on the board of Atmos XR, a technology company. She earned her BA at Tufts University, her J.D. at Brooklyn Law School and was a fellow at the Harvard Advanced Leadership Initiative.
- Eric J. Ende
-
Eric J. Ende，医学博士，自2022年1月起担任Neubase Therapeutics，Inc.董事会成员。Ende博士是Ende BioMedical Consulting Group，Inc.的总裁。Ende BioMedical Consulting Group，Inc.是一家专注于生命科学行业的私营咨询公司，自2009年以来一直担任该职位。自2017年5月起，恩德博士成为Matinas BioPharma，Inc.（纽约证券交易所代码：MTNB）的董事会成员，该公司是一家临床阶段的生物制药公司，担任薪酬委员会主席，并在审计委员会、提名与公司治理委员会任职。自2018年12月起，恩德博士成为Avadel plc（纳斯达克股票代码：99目录AVDL）的董事会成员，该公司是一家临床阶段的生物制药公司，担任提名与公司治理委员会主席并担任审计委员会成员。2019年11月至2020年6月，恩德博士在生物制药公司Progenics Pharmaceuticals, Inc.（Nasdaq：PGNX）董事会任职，并担任薪酬委员会主席、审计委员会和科学委员会成员。2010年至2011年，Ende博士担任生物技术公司Genzyme Corp.（Nasdaq：GENZ）的董事会成员和审计和风险管理委员会成员，直到2011年被Sanofi S.A.收购。2002年至2008年，Ende博士担任美林证券的高级生物技术分析师；2000年至2002年，他担任美国银行证券的高级生物技术分析师；1997年至2000年，他担任雷曼兄弟的生物技术分析师。Ende博士于1997年获得纽约大学斯特恩商学院的金融和会计MBA学位，1994年获得西奈山医学院的医学博士学位，1990年获得埃默里大学的生物学和心理学学士学位。
Eric J. Ende,M.D., has served as a member of Neubase Therapeutics, Inc. Board since January 2022. Dr. Ende is the President of Ende BioMedical Consulting Group, Inc., a privately held consulting company focused on the life sciences industry, a position he has held since 2009. Since May 2017, Dr. Ende has been a member of the board of directors of Matinas BioPharma, Inc. (NYSE: MTNB), a clinical-stage biopharmaceutical company, where he chairs the Compensation Committee and serves on the Audit and Nominating & Corporate Governance Committees. Since December 2018, Dr. Ende has been a member of the board of directors of Avadel plc (Nasdaq: 99 Table of Contents AVDL), a clinical-stage biopharmaceutical company, where he chairs the Nominating & Corporate Governance Committee and serves on the Audit Committee. From November 2019 to June 2020, Dr. Ende served on the board of directors of Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), a biopharmaceutical company, where he also chaired the Compensation Committee and was a member of the Audit and Science Committees. From 2010 to 2011, Dr. Ende served on the board of directors and as a member of the Audit and Risk Management Committees of Genzyme Corp. (Nasdaq: GENZ), a biotechnology company, until it was acquired in 2011 by Sanofi S.A. From 2002 through 2008, Dr. Ende was the senior biotechnology analyst at Merrill Lynch; from 2000 through 2002, he was the senior biotechnology analyst at Bank of America Securities; and from 1997 to 2000, he was a biotechnology analyst at Lehman Brothers. Dr. Ende received an MBA in Finance and Accounting from NYU-Stern Business School in 1997, an MD from Mount Sinai School of Medicine in 1994, and a BS in Biology and Psychology from Emory University in 1990. - Eric J. Ende，医学博士，自2022年1月起担任Neubase Therapeutics，Inc.董事会成员。Ende博士是Ende BioMedical Consulting Group，Inc.的总裁。Ende BioMedical Consulting Group，Inc.是一家专注于生命科学行业的私营咨询公司，自2009年以来一直担任该职位。自2017年5月起，恩德博士成为Matinas BioPharma，Inc.（纽约证券交易所代码：MTNB）的董事会成员，该公司是一家临床阶段的生物制药公司，担任薪酬委员会主席，并在审计委员会、提名与公司治理委员会任职。自2018年12月起，恩德博士成为Avadel plc（纳斯达克股票代码：99目录AVDL）的董事会成员，该公司是一家临床阶段的生物制药公司，担任提名与公司治理委员会主席并担任审计委员会成员。2019年11月至2020年6月，恩德博士在生物制药公司Progenics Pharmaceuticals, Inc.（Nasdaq：PGNX）董事会任职，并担任薪酬委员会主席、审计委员会和科学委员会成员。2010年至2011年，Ende博士担任生物技术公司Genzyme Corp.（Nasdaq：GENZ）的董事会成员和审计和风险管理委员会成员，直到2011年被Sanofi S.A.收购。2002年至2008年，Ende博士担任美林证券的高级生物技术分析师；2000年至2002年，他担任美国银行证券的高级生物技术分析师；1997年至2000年，他担任雷曼兄弟的生物技术分析师。Ende博士于1997年获得纽约大学斯特恩商学院的金融和会计MBA学位，1994年获得西奈山医学院的医学博士学位，1990年获得埃默里大学的生物学和心理学学士学位。
- Eric J. Ende,M.D., has served as a member of Neubase Therapeutics, Inc. Board since January 2022. Dr. Ende is the President of Ende BioMedical Consulting Group, Inc., a privately held consulting company focused on the life sciences industry, a position he has held since 2009. Since May 2017, Dr. Ende has been a member of the board of directors of Matinas BioPharma, Inc. (NYSE: MTNB), a clinical-stage biopharmaceutical company, where he chairs the Compensation Committee and serves on the Audit and Nominating & Corporate Governance Committees. Since December 2018, Dr. Ende has been a member of the board of directors of Avadel plc (Nasdaq: 99 Table of Contents AVDL), a clinical-stage biopharmaceutical company, where he chairs the Nominating & Corporate Governance Committee and serves on the Audit Committee. From November 2019 to June 2020, Dr. Ende served on the board of directors of Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), a biopharmaceutical company, where he also chaired the Compensation Committee and was a member of the Audit and Science Committees. From 2010 to 2011, Dr. Ende served on the board of directors and as a member of the Audit and Risk Management Committees of Genzyme Corp. (Nasdaq: GENZ), a biotechnology company, until it was acquired in 2011 by Sanofi S.A. From 2002 through 2008, Dr. Ende was the senior biotechnology analyst at Merrill Lynch; from 2000 through 2002, he was the senior biotechnology analyst at Bank of America Securities; and from 1997 to 2000, he was a biotechnology analyst at Lehman Brothers. Dr. Ende received an MBA in Finance and Accounting from NYU-Stern Business School in 1997, an MD from Mount Sinai School of Medicine in 1994, and a BS in Biology and Psychology from Emory University in 1990.
- Bradley L. Campbell
-
Bradley L. Campbell，自2013年12月，他曾担任首席运营官，自2012年2月为首席商务官。2010年1月至2012年2月他担任业务运营高级副总裁；从2007年5月至2010年1月担任业务规划副总裁，并从2006年4月至2007年5月为业务发展高级总监。他担任Myozyme的庞贝氏症的高级产品经理，后来从2002年至2006年担任Genzyme公司的心血管基因治疗业务总监。他还曾在 Bristol-Myers Squibb的销售和市场营销部门工作，并为 Marakon Associates的企业战略顾问。他获得杜克大学的学士学位和哈佛商学院工商管理硕士学位。
Bradley L. Campbell has served as a member of the Board since June 2018 and as President and Chief Operating Officer since January 2015. Mr. Campbell served as Chief Operating Officer since December 2013 and, prior thereto, as Chief Business Officer since February 2012. From January 2010 to February 2012 Mr. Campbell served as Senior Vice President, Business Operations; from May 2007 to January 2010 as Vice President, Business Planning and from April 2006 until May 2007 as Senior Director, Business Development. Mr. Campbell served as Senior Product Manager of Myozyme©- for Pompe Disease and later as Business Director of CV Gene Therapy at Genzyme Corporation from 2002 to 2006. Mr. Campbell has also worked in sales & marketing for Bristol Myers Squibb and as a business strategy consultant for Marakon Associates. Currently, Mr. Campbell also serves as a director for ARYA Sciences Acquisitions Corp III NASDAQ: ARYA and previously served as a director of Progenics (NASDAQ: PGNX). Mr. Campbell received his B.A. from Duke University and his M.B.A. from Harvard Business School. - Bradley L. Campbell，自2013年12月，他曾担任首席运营官，自2012年2月为首席商务官。2010年1月至2012年2月他担任业务运营高级副总裁；从2007年5月至2010年1月担任业务规划副总裁，并从2006年4月至2007年5月为业务发展高级总监。他担任Myozyme的庞贝氏症的高级产品经理，后来从2002年至2006年担任Genzyme公司的心血管基因治疗业务总监。他还曾在 Bristol-Myers Squibb的销售和市场营销部门工作，并为 Marakon Associates的企业战略顾问。他获得杜克大学的学士学位和哈佛商学院工商管理硕士学位。
- Bradley L. Campbell has served as a member of the Board since June 2018 and as President and Chief Operating Officer since January 2015. Mr. Campbell served as Chief Operating Officer since December 2013 and, prior thereto, as Chief Business Officer since February 2012. From January 2010 to February 2012 Mr. Campbell served as Senior Vice President, Business Operations; from May 2007 to January 2010 as Vice President, Business Planning and from April 2006 until May 2007 as Senior Director, Business Development. Mr. Campbell served as Senior Product Manager of Myozyme©- for Pompe Disease and later as Business Director of CV Gene Therapy at Genzyme Corporation from 2002 to 2006. Mr. Campbell has also worked in sales & marketing for Bristol Myers Squibb and as a business strategy consultant for Marakon Associates. Currently, Mr. Campbell also serves as a director for ARYA Sciences Acquisitions Corp III NASDAQ: ARYA and previously served as a director of Progenics (NASDAQ: PGNX). Mr. Campbell received his B.A. from Duke University and his M.B.A. from Harvard Business School.
- Karen J. Ferrante
-
Karen J. Ferrante，医学博士，自2014年4月以来担任我们研发的主管和首席医疗官。在加入我们公司之前，她从2013年5月到2013年7月担任Takeda Pharmaceuticals肿瘤治疗领域主管和Takeda Cambridge美国网站主管，在Millennium Pharmaceuticals（2008年5月被Takeda Pharmaceuticals收购）担任高级职位，包括从2007年9月到2013年5月担任首席医疗官，研发的主管和临床发展的高级副总裁。此外，她之前在Pfizer Global Research & Development（辉瑞全球研发）担任职位，责任不断增加，包括担任副总裁和肿瘤学发展临床治疗领域的领导者，并担任Bristol-Myers Squibb Company（或BMS）临床肿瘤的副董事。加入BMS之前，她担任Beth Israel Deaconess Hospital的主治医师。她还担任哈佛医学院（Harvard Medical School）的讲师，临床教师和医学临床研究员，同时在Beth Israel Deaconess Hospital血液学和肿瘤学完成实习医师和住院医师职务（随后获得研究员职位）。目前，他担任Progenics Pharmaceuticals, Inc.的董事会成员。他获得普罗维登斯大学（Providence College）的化学和生物学学士学位以及乔治城大学（Georgetown University）的医学博士学位。
Karen J. Ferrante joined our Board in January 2014. From April 2014 to August 2016 she was the head of Research and Development and Chief Medical Officer of Tokai Pharmaceuticals, Inc., a publicly traded biopharmaceutical company developing treatments for prostate cancer and other hormonally driven diseases. From 2007 to July 2013 Dr. Ferrante held senior positions at Millennium Pharmaceuticals, Inc. and its parent company, Takeda Pharmaceutical Company Limited, including Chief Medical Officer and most recently as Oncology Therapeutic Area Head and Cambridge USA Site Head from May 2013 to July 2013. From 1999 to 2007 she held positions of increasing responsibility at Pfizer Global Research & Development, culminating as Vice President, Oncology Development. She began her career in the pharmaceutical industry in 1995 as Associate Director of Clinical Oncology at Bristol-Myers Squibb Company. Prior to that, she was at the New England Deaconess Hospital in Boston Beth Israel Deaconess, where she completed her internship and residency in internal medicine followed by her fellowship in hematology and oncology. While at Beth Israel Deaconess, she served as Instructor, Clinical Instructor and Clinical Fellow in Medicine at the Harvard Medical School. Dr. Ferrante serves on the Boards of MacroGenics, Inc., a publicly traded clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, autoimmune disorders and infectious diseases; Hutchinson China MediTech Limited, a publicly traded innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and health care products; and, since February 2018 Unum Therapeutics Inc., a publicly traded clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products. Dr. Ferrante also served as a director of Baxalta Inc., a publicly traded global biopharmaceutical company until its acquisition by Shire Pharmaceuticals in June 2016. She holds a B.S. in Chemistry and Biology from Providence College and an M.D. from Georgetown University; she has also been an author of a number of papers in the oncology field, is an active participant in academic and professional associations and symposia, and holds several patents. - Karen J. Ferrante，医学博士，自2014年4月以来担任我们研发的主管和首席医疗官。在加入我们公司之前，她从2013年5月到2013年7月担任Takeda Pharmaceuticals肿瘤治疗领域主管和Takeda Cambridge美国网站主管，在Millennium Pharmaceuticals（2008年5月被Takeda Pharmaceuticals收购）担任高级职位，包括从2007年9月到2013年5月担任首席医疗官，研发的主管和临床发展的高级副总裁。此外，她之前在Pfizer Global Research & Development（辉瑞全球研发）担任职位，责任不断增加，包括担任副总裁和肿瘤学发展临床治疗领域的领导者，并担任Bristol-Myers Squibb Company（或BMS）临床肿瘤的副董事。加入BMS之前，她担任Beth Israel Deaconess Hospital的主治医师。她还担任哈佛医学院（Harvard Medical School）的讲师，临床教师和医学临床研究员，同时在Beth Israel Deaconess Hospital血液学和肿瘤学完成实习医师和住院医师职务（随后获得研究员职位）。目前，他担任Progenics Pharmaceuticals, Inc.的董事会成员。他获得普罗维登斯大学（Providence College）的化学和生物学学士学位以及乔治城大学（Georgetown University）的医学博士学位。
- Karen J. Ferrante joined our Board in January 2014. From April 2014 to August 2016 she was the head of Research and Development and Chief Medical Officer of Tokai Pharmaceuticals, Inc., a publicly traded biopharmaceutical company developing treatments for prostate cancer and other hormonally driven diseases. From 2007 to July 2013 Dr. Ferrante held senior positions at Millennium Pharmaceuticals, Inc. and its parent company, Takeda Pharmaceutical Company Limited, including Chief Medical Officer and most recently as Oncology Therapeutic Area Head and Cambridge USA Site Head from May 2013 to July 2013. From 1999 to 2007 she held positions of increasing responsibility at Pfizer Global Research & Development, culminating as Vice President, Oncology Development. She began her career in the pharmaceutical industry in 1995 as Associate Director of Clinical Oncology at Bristol-Myers Squibb Company. Prior to that, she was at the New England Deaconess Hospital in Boston Beth Israel Deaconess, where she completed her internship and residency in internal medicine followed by her fellowship in hematology and oncology. While at Beth Israel Deaconess, she served as Instructor, Clinical Instructor and Clinical Fellow in Medicine at the Harvard Medical School. Dr. Ferrante serves on the Boards of MacroGenics, Inc., a publicly traded clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, autoimmune disorders and infectious diseases; Hutchinson China MediTech Limited, a publicly traded innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and health care products; and, since February 2018 Unum Therapeutics Inc., a publicly traded clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products. Dr. Ferrante also served as a director of Baxalta Inc., a publicly traded global biopharmaceutical company until its acquisition by Shire Pharmaceuticals in June 2016. She holds a B.S. in Chemistry and Biology from Providence College and an M.D. from Georgetown University; she has also been an author of a number of papers in the oncology field, is an active participant in academic and professional associations and symposia, and holds several patents.
高管简历
中英对照 | 中文 | 英文- Patrick Fabbio
Patrick Fabbio于2015年11月加入本公司，担任高级副总裁兼首席财务官。在加入Progenics之前，他是electroCore（一家私人持有的生物电疗医疗公司）的首席财务官，以及NPS Pharmaceuticals, Inc.（一家上市的全球罕见疾病公司）的财务副总裁。 Fabbio先生在公共和私人生命科学和制药公司拥有超过20年的财务领导经验，包括：Catalent Pharma Solutions金融的副总裁；Ikano Therapeutics的首席财务官；Sanofi高级企业融资，商业和交易职位；和Biomatrix Inc.（一家公开上市的生物技术公司，被Genzyme收购）的公司财务主管。他毕业于 Pace University会计学的商学士学位和Stern School of Business at New York University的金融硕士学位。他在新泽西州获得了注册会计师执照。
Patrick Fabbio,has served on board since January 2018. Mr. Fabbio is currently the Chief Financial Officer of Protara Therapeutics, Inc. Mr. Fabbio has more than 30 years of financial, operational and transactional leadership experience in both publicly-traded and privately-held life science and pharmaceutical companies. Prior to joining Protara Therapeutics, Inc., Mr. Fabbio was Chief Financial Officer of Rafael Holdings, Inc. Previously he served as the Chief Financial Officer of WindMIL Therapeutics Inc., Progenics Pharmaceuticals, Inc., electroCore Medical, LLC; Vice President of Finance at NPS Pharmaceuticals, Inc.; Vice President of Finance, Innovation and Growth at Catalent Pharma Solutions Inc.; and Chief Financial Officer at Ikano Therapeutics. His other prior financial positions include roles at Sanofi, UniPath Diagnostics, BioMatrix and Coopers & Lybrand. He received his B.B.A. in accounting at Pace University and MBA from the Stern School of Business at New York University.- Patrick Fabbio于2015年11月加入本公司，担任高级副总裁兼首席财务官。在加入Progenics之前，他是electroCore（一家私人持有的生物电疗医疗公司）的首席财务官，以及NPS Pharmaceuticals, Inc.（一家上市的全球罕见疾病公司）的财务副总裁。 Fabbio先生在公共和私人生命科学和制药公司拥有超过20年的财务领导经验，包括：Catalent Pharma Solutions金融的副总裁；Ikano Therapeutics的首席财务官；Sanofi高级企业融资，商业和交易职位；和Biomatrix Inc.（一家公开上市的生物技术公司，被Genzyme收购）的公司财务主管。他毕业于 Pace University会计学的商学士学位和Stern School of Business at New York University的金融硕士学位。他在新泽西州获得了注册会计师执照。
- Patrick Fabbio,has served on board since January 2018. Mr. Fabbio is currently the Chief Financial Officer of Protara Therapeutics, Inc. Mr. Fabbio has more than 30 years of financial, operational and transactional leadership experience in both publicly-traded and privately-held life science and pharmaceutical companies. Prior to joining Protara Therapeutics, Inc., Mr. Fabbio was Chief Financial Officer of Rafael Holdings, Inc. Previously he served as the Chief Financial Officer of WindMIL Therapeutics Inc., Progenics Pharmaceuticals, Inc., electroCore Medical, LLC; Vice President of Finance at NPS Pharmaceuticals, Inc.; Vice President of Finance, Innovation and Growth at Catalent Pharma Solutions Inc.; and Chief Financial Officer at Ikano Therapeutics. His other prior financial positions include roles at Sanofi, UniPath Diagnostics, BioMatrix and Coopers & Lybrand. He received his B.B.A. in accounting at Pace University and MBA from the Stern School of Business at New York University.
- Asha Das
Asha Das于2019年1月加入我们，担任首席医疗官。Das博士最近担任Tocagen Inc.的首席医疗官，在那里她领导公司的癌症选择性基因治疗平台的开发。2008年4月至2015年4月，Das博士在Genentech Inc.（Roche Group的成员）担任越来越重要的职位，最初担任副医疗总监，最终担任集团医疗总监。她曾负责领导Avastin在复发性胶质母细胞瘤的批准和推出，向铂类耐药卵巢癌和转移性宫颈癌的扩展以及与Tecentriq®；相关的临床活动。从2005年到2008年，她曾担任Eisai公司（制药公司）的副医疗董事，在那里她专注于肿瘤疗法Halaven®；和Lenvima™；的临床活动。在此之前，Das博士是Cedars-Sinai Medical Center神经肿瘤学项目的负责人。DAS获得美国精神病学和神经病学委员会（American Board of Psychiatry and Neurology）神经病学认证，并获得联合神经学次专科委员会（United Council for Neurological Subspecialties）神经肿瘤学认证，此前曾担任马萨诸塞州总医院（Massachusetts General Hospital）神经肿瘤学临床研究员。Das博士在康奈尔医学中心（Cornell Medical Center）完成神经病学住院医师学位，并在加州大学洛杉矶分校、加州大学旧金山分校和新加坡国立大学（National University of Singapore）担任学术职务。Das博士在康奈尔大学（Cornell University）获得医学学位和学士学位。
Asha Das joined us in January 2019 as Chief Medical Officer. Dr. Das most recently served as Tocagen Inc.’s Chief Medical Officer, where she led the development of the company’s cancer-selective gene therapy platform. From April 2008 to April 2015 Dr. Das served at Genentech Inc., a member of the Roche Group, in positions of increasing responsibility, initially as Associate Medical Director and ultimately as Group Medical Director. She was responsible for leading activities related to the approval and launch of Avastin in recurrent glioblastoma, expansion into platinum-resistant ovarian cancer and metastatic cervical cancer as well as clinical activities related to TECENTRIQ®. From 2005 to 2008 Dr. Das served as Associate Medical Director at Eisai Inc., a pharmaceutical company, where she focused on clinical activities related to the oncology therapeutics HALAVEN® and LENVIMA™. Prior to that, Dr. Das was head of the neuro-oncology program at Cedars-Sinai Medical Center.Dr. Das is certified in neurology by the American Board of Psychiatry and Neurology and in the sub-specialty of neuro-oncology by the United Council for Neurologic Subspecialties and previously served as a clinical fellow in neuro-oncology at Massachusetts General Hospital. Dr. Das completed her residency in neurology at Cornell Medical Center and has held academic appointments at the University of California, Los Angeles; University of California, San Francisco; and National University of Singapore. Dr. Das obtained her medical degree and bachelor’s degree from Cornell University.- Asha Das于2019年1月加入我们，担任首席医疗官。Das博士最近担任Tocagen Inc.的首席医疗官，在那里她领导公司的癌症选择性基因治疗平台的开发。2008年4月至2015年4月，Das博士在Genentech Inc.（Roche Group的成员）担任越来越重要的职位，最初担任副医疗总监，最终担任集团医疗总监。她曾负责领导Avastin在复发性胶质母细胞瘤的批准和推出，向铂类耐药卵巢癌和转移性宫颈癌的扩展以及与Tecentriq®；相关的临床活动。从2005年到2008年，她曾担任Eisai公司（制药公司）的副医疗董事，在那里她专注于肿瘤疗法Halaven®；和Lenvima™；的临床活动。在此之前，Das博士是Cedars-Sinai Medical Center神经肿瘤学项目的负责人。DAS获得美国精神病学和神经病学委员会（American Board of Psychiatry and Neurology）神经病学认证，并获得联合神经学次专科委员会（United Council for Neurological Subspecialties）神经肿瘤学认证，此前曾担任马萨诸塞州总医院（Massachusetts General Hospital）神经肿瘤学临床研究员。Das博士在康奈尔医学中心（Cornell Medical Center）完成神经病学住院医师学位，并在加州大学洛杉矶分校、加州大学旧金山分校和新加坡国立大学（National University of Singapore）担任学术职务。Das博士在康奈尔大学（Cornell University）获得医学学位和学士学位。
- Asha Das joined us in January 2019 as Chief Medical Officer. Dr. Das most recently served as Tocagen Inc.’s Chief Medical Officer, where she led the development of the company’s cancer-selective gene therapy platform. From April 2008 to April 2015 Dr. Das served at Genentech Inc., a member of the Roche Group, in positions of increasing responsibility, initially as Associate Medical Director and ultimately as Group Medical Director. She was responsible for leading activities related to the approval and launch of Avastin in recurrent glioblastoma, expansion into platinum-resistant ovarian cancer and metastatic cervical cancer as well as clinical activities related to TECENTRIQ®. From 2005 to 2008 Dr. Das served as Associate Medical Director at Eisai Inc., a pharmaceutical company, where she focused on clinical activities related to the oncology therapeutics HALAVEN® and LENVIMA™. Prior to that, Dr. Das was head of the neuro-oncology program at Cedars-Sinai Medical Center.Dr. Das is certified in neurology by the American Board of Psychiatry and Neurology and in the sub-specialty of neuro-oncology by the United Council for Neurologic Subspecialties and previously served as a clinical fellow in neuro-oncology at Massachusetts General Hospital. Dr. Das completed her residency in neurology at Cornell Medical Center and has held academic appointments at the University of California, Los Angeles; University of California, San Francisco; and National University of Singapore. Dr. Das obtained her medical degree and bachelor’s degree from Cornell University.
- David W. Mims
DavidW.Mims，临时首席执行官，于2019年11月加入董事会。Mims先生自2017年5月起担任Guideway Care（一家梦百合公司，提供技术支持的护理指导）和SouthPoint Bank（一家社区银行机构）的董事会成员。此前，2011年5月至2014年5月，Mims先生曾担任私人制药公司Aptalis Pharma Inc.（F/K/A Axcan Pharma Inc.）的美国专业制药总裁，该公司被森林实验室公司（纽约证券交易所代码:FRX）收购后不久，他在该公司管理着200多名员工。Mims从2008年2月到2014年5月担任Axcan Intermediate Holdings Inc.（Axcan Pharma Inc.（前身为TSE:AXP和NASDAQ:AXCA）母公司）美国专业制药总裁，从2000年到2007年担任董事会成员。Mims先生于2000年开始在Axcan Pharma Inc.担任执行Vice President和首席运营官，此前该公司收购了ScandiPharm，Inc.，后者是一家私人控股的制药公司，Mims先生帮助建立了该公司，他曾担任该公司的Vice President、首席运营官和首席财务官，从1991年到1998年。目前，Mims先生担任美国注册会计师协会和阿拉巴马注册会计师协会的成员。此前，Mims先生担任阿拉巴马大学伯明翰研究基金会（University of Alabama at Birmingham Research Foundation）的董事。Mims先生是一名有执照的注册会计师（不活跃）。Mims先生在奥本大学（Auburn University）获得会计学学士学位。
David W. Mims, Interim CEO, joined our Board in November 2019. Mr. Mims has served as a member of the board of directors at each of Guideway Care, a healthcare company that provides technology-enabled care guidance, since May 2017 and SouthPoint Bank, a community banking institution, since August 2015. Previously, Mr. Mims served as President at U.S. Specialty Pharmaceuticals for Aptalis Pharma Inc. “Aptalis” (f/k/a Axcan Pharma Inc.), a privately held pharmaceutical company, from May 2011 until May 2014 shortly after it was acquired by Forest Laboratories, Inc. (formerly NYSE: FRX) and where he managed over 200 employees. Mr. Mims similarly served as President of U.S. Specialty Pharmaceuticals at Axcan Intermediate Holdings Inc., the parent company of Axcan Pharma Inc. (formerly TSE: AXP and NAsdaq: AXCA), from February 2008 until May 2014 and as a member on its board from 2000 to 2007. Mr. Mims began working at Axcan Pharma Inc. as Executive Vice President and Chief Operating Officer in 2000 after the company acquired Scandipharm, Inc., a privately held pharmaceutical company, which Mr. Mims helped found and for which he served as Vice President, Chief Operating Officer and Chief Financial Officer, from 1991 until 1998. Currently, Mr. Mims serves as a member of the American Institute of Certified Public Accountants and Alabama Society of Certified Public Accountants. Previously, Mr. Mims served as a director of the University of Alabama at Birmingham Research Foundation. Mr. Mims is a licensed CPA (inactive). Mr. Mims received his B.S. in accounting from Auburn University.- DavidW.Mims，临时首席执行官，于2019年11月加入董事会。Mims先生自2017年5月起担任Guideway Care（一家梦百合公司，提供技术支持的护理指导）和SouthPoint Bank（一家社区银行机构）的董事会成员。此前，2011年5月至2014年5月，Mims先生曾担任私人制药公司Aptalis Pharma Inc.（F/K/A Axcan Pharma Inc.）的美国专业制药总裁，该公司被森林实验室公司（纽约证券交易所代码:FRX）收购后不久，他在该公司管理着200多名员工。Mims从2008年2月到2014年5月担任Axcan Intermediate Holdings Inc.（Axcan Pharma Inc.（前身为TSE:AXP和NASDAQ:AXCA）母公司）美国专业制药总裁，从2000年到2007年担任董事会成员。Mims先生于2000年开始在Axcan Pharma Inc.担任执行Vice President和首席运营官，此前该公司收购了ScandiPharm，Inc.，后者是一家私人控股的制药公司，Mims先生帮助建立了该公司，他曾担任该公司的Vice President、首席运营官和首席财务官，从1991年到1998年。目前，Mims先生担任美国注册会计师协会和阿拉巴马注册会计师协会的成员。此前，Mims先生担任阿拉巴马大学伯明翰研究基金会（University of Alabama at Birmingham Research Foundation）的董事。Mims先生是一名有执照的注册会计师（不活跃）。Mims先生在奥本大学（Auburn University）获得会计学学士学位。
- David W. Mims, Interim CEO, joined our Board in November 2019. Mr. Mims has served as a member of the board of directors at each of Guideway Care, a healthcare company that provides technology-enabled care guidance, since May 2017 and SouthPoint Bank, a community banking institution, since August 2015. Previously, Mr. Mims served as President at U.S. Specialty Pharmaceuticals for Aptalis Pharma Inc. “Aptalis” (f/k/a Axcan Pharma Inc.), a privately held pharmaceutical company, from May 2011 until May 2014 shortly after it was acquired by Forest Laboratories, Inc. (formerly NYSE: FRX) and where he managed over 200 employees. Mr. Mims similarly served as President of U.S. Specialty Pharmaceuticals at Axcan Intermediate Holdings Inc., the parent company of Axcan Pharma Inc. (formerly TSE: AXP and NAsdaq: AXCA), from February 2008 until May 2014 and as a member on its board from 2000 to 2007. Mr. Mims began working at Axcan Pharma Inc. as Executive Vice President and Chief Operating Officer in 2000 after the company acquired Scandipharm, Inc., a privately held pharmaceutical company, which Mr. Mims helped found and for which he served as Vice President, Chief Operating Officer and Chief Financial Officer, from 1991 until 1998. Currently, Mr. Mims serves as a member of the American Institute of Certified Public Accountants and Alabama Society of Certified Public Accountants. Previously, Mr. Mims served as a director of the University of Alabama at Birmingham Research Foundation. Mr. Mims is a licensed CPA (inactive). Mr. Mims received his B.S. in accounting from Auburn University.
- Bryce Tenbarge
Bryce Tenbarge于2016年8月加入我们，目前担任高级副总裁，Commercial。在加入我们之前，他是Celldex Therapeutics（一家公开上市的生物技术公司）营销和商业化的Vice President。Tenbarge先生在高度专业化的产品方面拥有超过15年的商业领导经验，包括:Teva Pharmaceuticals的全球肿瘤营销高级总监，以及百时美施贵宝公司在专业和付款人营销、市场研究和商业智能方面越来越重要的各种角色。Tenbarge先生在密歇根大学（University of Michigan）罗斯商学院（Ross School of Business）获得工商管理硕士学位之前，在芝加哥Archer Daniels Midland担任商品交易员开始他的职业生涯。
Bryce Tenbarge joined us in August 2016 and currently serves as Senior Vice President, Commercial. Prior to joining us, he was Vice President of Marketing and Commercialization at Celldex Therapeutics, a publicly-traded biotechnology company. Mr. Tenbarge has more than 15 years of commercial leadership experience with highly specialized products including: Senior Director of Global Oncology Marketing at Teva Pharmaceuticals and a variety of roles of increasing responsibility at Bristol-Myers Squibb Company in professional and payer marketing, market research and business intelligence. Mr. Tenbarge started his career as a commodity trader at Archer Daniels Midland in Chicago prior to receiving his M.B.A. from The Ross School of Business at the University of Michigan.- Bryce Tenbarge于2016年8月加入我们，目前担任高级副总裁，Commercial。在加入我们之前，他是Celldex Therapeutics（一家公开上市的生物技术公司）营销和商业化的Vice President。Tenbarge先生在高度专业化的产品方面拥有超过15年的商业领导经验，包括:Teva Pharmaceuticals的全球肿瘤营销高级总监，以及百时美施贵宝公司在专业和付款人营销、市场研究和商业智能方面越来越重要的各种角色。Tenbarge先生在密歇根大学（University of Michigan）罗斯商学院（Ross School of Business）获得工商管理硕士学位之前，在芝加哥Archer Daniels Midland担任商品交易员开始他的职业生涯。
- Bryce Tenbarge joined us in August 2016 and currently serves as Senior Vice President, Commercial. Prior to joining us, he was Vice President of Marketing and Commercialization at Celldex Therapeutics, a publicly-traded biotechnology company. Mr. Tenbarge has more than 15 years of commercial leadership experience with highly specialized products including: Senior Director of Global Oncology Marketing at Teva Pharmaceuticals and a variety of roles of increasing responsibility at Bristol-Myers Squibb Company in professional and payer marketing, market research and business intelligence. Mr. Tenbarge started his career as a commodity trader at Archer Daniels Midland in Chicago prior to receiving his M.B.A. from The Ross School of Business at the University of Michigan.
- Benedict Osorio
Benedict Osorio先生，于2005年加盟我公司，目前是我公司的质量监管部高级副主管。他拥有超过三十年的药品质量控制和质量保证经验，包括在2001年到2005年期间作为森林实验室（Forest Laboratories）的董事及高级总监。1984年至2001年，Osorio先生曾在PF普渡大学实验室（The PF Laboratories）担任责任重大的职务，最终担任其质量保证部执行董事，该机构是普度制药公司（Purdue Pharma）的一家子公司。1979年到1984年，他是伯莱克斯实验室（Berlex Laboratories）的一名化学分析家。他获得M.B.A。和。M.S。从西顿霍尔大学（Seton Hall University ）化学学士学位和工商管理硕士学位，以及约翰·杰伊学院法医学（John Jay College of Criminal Justice）刑事司法学士学位。
Benedict Osorio initially joined us in July 2005 until October 2012 and returned in February 2018 and is currently our COO. He has over three decades of experience in pharmaceutical quality control and quality assurance, including service as Vice President, Quality Assurance at Acorda Therapeutics, Vice President, Quality Assurance at Achillion Pharmaceuticals, Vice President, Quality Operations North America at Valeant Pharmaceuticals, Global Head of Quality for Braeburn Pharmaceuticals, Senior Consultant at Complya Consulting, Vice President and Senior Vice President, Quality at Progenics Pharmaceuticals, Director and Senior Director at Forest Laboratories, various positions of increasing responsibility with The PF Laboratories a subsidiary of Purdue Pharma, ultimately as Executive Director, Quality Assurance and analytical chemist with Berlex Laboratories. He earned both an M.B.A. and an M.S. in chemistry from Seton Hall University and a B.S. in forensic science from John Jay College of Criminal Justice.- Benedict Osorio先生，于2005年加盟我公司，目前是我公司的质量监管部高级副主管。他拥有超过三十年的药品质量控制和质量保证经验，包括在2001年到2005年期间作为森林实验室（Forest Laboratories）的董事及高级总监。1984年至2001年，Osorio先生曾在PF普渡大学实验室（The PF Laboratories）担任责任重大的职务，最终担任其质量保证部执行董事，该机构是普度制药公司（Purdue Pharma）的一家子公司。1979年到1984年，他是伯莱克斯实验室（Berlex Laboratories）的一名化学分析家。他获得M.B.A。和。M.S。从西顿霍尔大学（Seton Hall University ）化学学士学位和工商管理硕士学位，以及约翰·杰伊学院法医学（John Jay College of Criminal Justice）刑事司法学士学位。
- Benedict Osorio initially joined us in July 2005 until October 2012 and returned in February 2018 and is currently our COO. He has over three decades of experience in pharmaceutical quality control and quality assurance, including service as Vice President, Quality Assurance at Acorda Therapeutics, Vice President, Quality Assurance at Achillion Pharmaceuticals, Vice President, Quality Operations North America at Valeant Pharmaceuticals, Global Head of Quality for Braeburn Pharmaceuticals, Senior Consultant at Complya Consulting, Vice President and Senior Vice President, Quality at Progenics Pharmaceuticals, Director and Senior Director at Forest Laboratories, various positions of increasing responsibility with The PF Laboratories a subsidiary of Purdue Pharma, ultimately as Executive Director, Quality Assurance and analytical chemist with Berlex Laboratories. He earned both an M.B.A. and an M.S. in chemistry from Seton Hall University and a B.S. in forensic science from John Jay College of Criminal Justice.
- Vivien Wong
Vivien Wong，目前，她担任高级副总裁负责运营和资产组合管理。2007年加入Progenics之前，她担任Theritas Pharmaceutical Consultants的负责人3年。从1989年到2004年，她在Emisphere Technologies、Vivoquest和美国新泽西再生元制药（ Regeneron Pharmaceuticals）担任临床前开发和药理学的职务并不断被提拔。她是同行评审期刊的30多篇科学论文的联合作者。她获得密西西比大学（ the Mississippi University ）女校的biology学士学位和马里兰大学（the University of Maryland ）医学院的解剖及神经生物学的博士学位。她还完成了爱因斯坦医学院（the Albert Einstein College of Medicine）的神经病学博士后研究。
Vivien Wong joined Progenics Pharmaceuticals, Inc. in September 2007 and currently serves as Executive Vice President, Development. For three years prior to joining Progenics Pharmaceuticals, Inc., Dr. Wong was Principal at Theritas Pharmaceutical Consultants. From 1989 to 2004 she held positions of increasing responsibility in preclinical development and pharmacology at Emisphere Technologies, Vivoquest, and Regeneron Pharmaceuticals. Dr. Wong has led the development and recent approval of AZEDRA by FDA, and played a key role in the approvals of Relistor Subcutaneous Injection and Relistor Tablets. Her pioneer research in pharmacology had paved the path for the development of Arcalyst, Eylea, Zaltrap, Kevzara, and Dupixent. Dr. Wong has been a co-author on over 30 scientific articles for peer-reviewed journals. She received a B.Sc. in biology from the Mississippi University for Women, a Ph.D. in anatomy and neurobiology from the University of Maryland School of Medicine, and completed a postdoctoral fellowship in neurology at the Albert Einstein College of Medicine.- Vivien Wong，目前，她担任高级副总裁负责运营和资产组合管理。2007年加入Progenics之前，她担任Theritas Pharmaceutical Consultants的负责人3年。从1989年到2004年，她在Emisphere Technologies、Vivoquest和美国新泽西再生元制药（ Regeneron Pharmaceuticals）担任临床前开发和药理学的职务并不断被提拔。她是同行评审期刊的30多篇科学论文的联合作者。她获得密西西比大学（ the Mississippi University ）女校的biology学士学位和马里兰大学（the University of Maryland ）医学院的解剖及神经生物学的博士学位。她还完成了爱因斯坦医学院（the Albert Einstein College of Medicine）的神经病学博士后研究。
- Vivien Wong joined Progenics Pharmaceuticals, Inc. in September 2007 and currently serves as Executive Vice President, Development. For three years prior to joining Progenics Pharmaceuticals, Inc., Dr. Wong was Principal at Theritas Pharmaceutical Consultants. From 1989 to 2004 she held positions of increasing responsibility in preclinical development and pharmacology at Emisphere Technologies, Vivoquest, and Regeneron Pharmaceuticals. Dr. Wong has led the development and recent approval of AZEDRA by FDA, and played a key role in the approvals of Relistor Subcutaneous Injection and Relistor Tablets. Her pioneer research in pharmacology had paved the path for the development of Arcalyst, Eylea, Zaltrap, Kevzara, and Dupixent. Dr. Wong has been a co-author on over 30 scientific articles for peer-reviewed journals. She received a B.Sc. in biology from the Mississippi University for Women, a Ph.D. in anatomy and neurobiology from the University of Maryland School of Medicine, and completed a postdoctoral fellowship in neurology at the Albert Einstein College of Medicine.